ArticleHaematologica2016

Response to Comment on Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.

Andrew H Lipsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.